124 related articles for article (PubMed ID: 27358900)
1. Acute promyelocytic leukemia co-existing with JAK2 V617F positive myeloproliferative neoplasm: a case report.
Mamorska-Dyga A; Wu J; Khattar P; Ronny FM; Islam H; Seiter K; Liu D
Stem Cell Investig; 2016; 3():8. PubMed ID: 27358900
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of a patient with
Jiang YZ; Wei ZL; Wang NN; Huang C; Huang J; Yan JW; Wang R; Yu ZZ; Huang DP
Hematology; 2022 Dec; 27(1):1290-1293. PubMed ID: 36476114
[TBL] [Abstract][Full Text] [Related]
3. FLT3 mutations in myeloproliferative neoplasms: the Beaumont experience.
Williams L; Kelley HH; Meng X; Prada A; Crisan D
Diagn Mol Pathol; 2013 Sep; 22(3):156-60. PubMed ID: 23846442
[TBL] [Abstract][Full Text] [Related]
4. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
[TBL] [Abstract][Full Text] [Related]
5. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
[TBL] [Abstract][Full Text] [Related]
6. Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome.
Braun TP; Maxson JE; Agarwal A; Dunlap J; Spurgeon SE; Traer E
Leuk Res Rep; 2015; 4(1):8-11. PubMed ID: 25628989
[TBL] [Abstract][Full Text] [Related]
7. Protracted Clonal Trajectory of a
Langabeer SE; Haslam K; Smyth MA; Quinn J; Murphy PT
Case Rep Hematol; 2018; 2018():8713020. PubMed ID: 29854499
[TBL] [Abstract][Full Text] [Related]
8. Secondary Acute Myeloid Leukemia in a One-Year-Old Girl Diagnosed with JAK2-V617F Mutation Positive Myeloproliferative Neoplasm.
Woods GM; Bajwa RP; Kahwash SB; Guinipero T
Case Rep Med; 2014; 2014():473297. PubMed ID: 24744787
[TBL] [Abstract][Full Text] [Related]
9. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
[TBL] [Abstract][Full Text] [Related]
10. [JAK2-V617F mutation in patients with myeloproliferative neoplasms: association with FLT3-ITD mutation].
Spasovski V; Tosić N; Kostić T; Pavlović S; Colović M
Srp Arh Celok Lek; 2010; 138(9-10):614-8. PubMed ID: 21180092
[TBL] [Abstract][Full Text] [Related]
11. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population.
Azevedo AP; Silva SN; Reichert A; Lima F; Júnior E; Rueff J
Biomed Rep; 2017 Oct; 7(4):370-376. PubMed ID: 29085634
[TBL] [Abstract][Full Text] [Related]
14. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
15. JAK2
Lin CH; Kaushansky K; Zhan H
Blood Cells Mol Dis; 2016 Nov; 62():42-48. PubMed ID: 27865175
[TBL] [Abstract][Full Text] [Related]
16. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
[TBL] [Abstract][Full Text] [Related]
18. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
19. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].
Funakoshi-Tago M
Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]